GOSS
Gossamer BioBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The best remaining bull argument is that PROSERA still showed activity signals despite missing the stricter alpha threshold, especially in intermediate/high-risk patients, and an FDA discussion could preserve a narrowed seralutinib path rather than a full reset.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Future financing or strategic actions could be highly dilutive at the current sub-$1 share price.
Momentum
38
Value
41
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.34 · Bull $0.55 · Bear $0.16
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-16 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $5.69
Why
Momentum38 · Δ7d -
Value41 · Δ7d +0.1
Sentiment100 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
38
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
100
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 38.0 / Value 41.1 / Sentiment 100.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$46.49M
Beta
1.94
Shares Out
231.46M
P/E (TTM) · Derived
-0.8
P/S (TTM)
14.40
P/FCF (TTM) · Derived
-0.29
Rev YoY
+40.2%
EPS YoY
-55.4%
Gross Margin
-
Op Margin
-365.1%
Net Debt
-$97M
Current Ratio
3.28
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology